1. Background {#sec147004}
=============

Insulin resistance is a measure of metabolic stress in patients undergoing surgery ([@A26207R1]). The magnitude of insulin resistance is associated with the severity and degree of the surgery. Major operations cause severe insulin resistance, while minor surgeries are correlated with mild resistance ([@A26207R1], [@A26207R2]). Insulin resistance increases 7- to 8-fold in adult patients undergoing elective major surgery ([@A26207R1]), and it usually extends to 3 weeks after the surgery ([@A26207R3], [@A26207R4]). The surgical technique is also important in this regard. Compared to laparoscopic techniques, open surgery techniques cause higher degrees of insulin resistance ([@A26207R1]).

In response to any trauma, such as surgery, several neuroendocrine changes occur, including increased plasma concentrations of cortisol, glucagon, and catecholamines, as well as increased levels of cytokines and immunologic responses ([@A26207R1], [@A26207R2]). These changes lead to a decreased insulin-to-glucagon ratio, and thus insulin resistance occurs ([@A26207R5], [@A26207R6]). Other factors also affect postoperative insulin resistance, such as postoperative oxidative stress, impaired function of skeletal muscle mitochondria, complete bed rest, and pain ([@A26207R1], [@A26207R3], [@A26207R7]).

As a stress marker, postoperative insulin resistance is closely associated with clinical outcomes ([@A26207R8]). In a study by Sato et al., insulin sensitivity that is decreased by 50% in patients undergoing abdominal surgery was related to 5 - 6 times as many major complications and 10 times as many severe infections. In other words, with a 1 mg/kg/minute decrease in insulin sensitivity, the incidence rates of major complications (OR: 2.23), severe infections (OR: 4.98), and minor infections (OR: 1.99) were increased ([@A26207R2]).

Perioperative insulin resistance is accompanied by hyperglycemia ([@A26207R5]). Acute hyperglycemia leads to increased inflammation, vulnerability to infection, and multiorgan system dysfunction via decreased nitric oxide production in the endothelium, decreased vasodilation, decreased complement function, increased cytokine levels, increased expression of adhesion molecules in leukocytes and endothelium, and impaired neutrophil chemotaxis and phagocytosis ([@A26207R6], [@A26207R9]). Based on Van den Berghe et al.'s study, even a moderate (6 - 8 mM) increase in perioperative glucose concentration leads to increased mortality and morbidity ([@A26207R10]).

Different approaches have been proposed to control perioperative insulin resistance, such as preoperative carbohydrate loading and early postoperative enteral feeding ([@A26207R3], [@A26207R11]). Studies have also revealed that metabolic conditioning using arginine, glutamine, and antioxidants helps to control insulin resistance in the perioperative period ([@A26207R3]). Glutamine can control insulin resistance by metabolic regulation pre- and postoperatively via decreased muscle cell injury, increased antioxidant capacity, and increased peripheral glucose utilization ([@A26207R3], [@A26207R12]). The results of a meta-analysis of 14 clinical trials showed that postoperative intravenous glutamine leads to decreased length of hospital stays and fewer complications in surgical patients ([@A26207R3], [@A26207R13]). It is also reported that using antioxidants, such as vitamin C and E, as preconditioning agents reduces free-radical-induced complications from surgery ([@A26207R14], [@A26207R15]).

A newly recognized preoperative metabolic regulatory factor, which is also considered an adjunctive therapy for type 2 diabetes mellitus, is L-carnitine ([@A26207R3], [@A26207R16]-[@A26207R18]). L-carnitine can control insulin resistance via increased fatty acid oxidation ([@A26207R19]). It also facilitates glucose utilization via increased pyruvate dehydrogenase activity ([@A26207R19]), and it can control postoperative oxidative stress ([@A26207R20]).

Before now, no clinical trial has evaluated the summative effects of carnitine, glutamine, and antioxidants. In a trial by Awad et al. ([@A26207R21]), the effects of an oral nutritional supplement containing carbohydrate, glutamine, and antioxidants were assessed in 20 patients undergoing laparoscopic cholecystectomy. Patients received either 600 mL of the supplement or a placebo the evening before surgery and an additional 300 mL 3 - 4 hours before anesthesia. A 300-mL aliquot of ONS contained 50 g of carbohydrate, 15 g of glutamine, and antioxidants. Intraoperative liver glycogen reserves, plasma glutamine, and antioxidant concentrations increased after supplement ingestion. Muscle pyruvate dehydrogenase kinase (PDK4), forkhead transcription factor 1 (FOXO1), and metallothionein 1A (a marker of cellular oxidative stress) expressions were lower in the supplement group. It was proposed that preoperative ingestion of this oral nutritional supplement can reduce insulin resistance through lowering muscle PDK4 mRNA and protein expression ([@A26207R21]).

2. Objectives {#sec147005}
=============

The role of insulin resistance is established in postoperative glycemic control and postsurgical morbidity and mortality, while metabolic conditioning agents such as glutamine, L-carnitine, and antioxidants play roles in the postoperative phase. In consideration of this, the present study aimed to determine the effects of a new metabolic conditioning supplement composed of glutamine, L-carnitine, vitamin C, vitamin E, and selenium, taken pre- and postoperatively, on perioperative metabolic stress and clinical surgical outcomes in non-diabetic patients.

3. Patients and Methods {#sec147012}
=======================

3.1. Study Participants {#sec147006}
-----------------------

The participants in the present study were selected from male and female patients scheduled for on-pump coronary artery bypass grafting (CABG) surgery at three government hospitals: Namazi, Faghihi, and Al-Zahra. These are referral hospitals for Shiraz University of Medical Sciences.

The inclusion criteria were age of 30 - 70 years, ejection fraction above 30%, serum creatinine level less than 1.5 mg/dL, undergoing on-pump CABG in one of the above-named hospitals, not taking antioxidant supplements in the previous month, and being included in the surgery schedule at least eight days before the operation. Patients scheduled for off-pump CABG, valve repair, or emergency operations, as well as those with diabetes mellitus, infectious disease, metabolic disease, humoral disease, immunological disease, or stroke, were excluded from the study.

The sample size was determined based on a trial on the effect of L-carnitine on HOMA-IR, an insulin resistance index ([@A26207R19]). Considering α = 0.05, 1-β = 0.90, difference = 0.8, and SD = 0.8, the sample size was calculated to be 22 patients in each arm (88 patients in the four groups). After eligible patients were identified, they were given oral and written explanations of the study, including its goal, benefits, and procedure, and were asked to read and sign an informed consent document. The study protocol was reviewed and approved by the Human Ethics Committee of the Research Council of the Deputy of Research Affairs of Shiraz University of Medical Sciences.

From June 2013 to March 2014, the patients who met all of the inclusion criteria and none of the exclusion criteria were enrolled consecutively, except for those who refused to enter the trial.

3.2. Supplement {#sec147007}
---------------

The supplement used in the present study was composed of glutamine (15 g), L-carnitine (3 g), vitamin C (750 mg), vitamin E (250 mg), and selenium (150 μg). This supplement was manufactured for the first time by the research team, under the supervision of a pharmaceutics specialist. The powders were mixed with a cubic mixer, and a homogenous powder was packed into sachet forms for daily use. The patients' instructions were to suspend the contents of one sachet in a glass of cold water and drink it after a meal.

The placebo sachets contained 5 g of starch powder. The same flavoring agent was used in the supplement and the placebo, and both types of sachet (drug and placebo) were tested blindly in volunteers to confirm that they were not distinguishable. There was no distinguishable difference in the packaging of the supplement and placebo.

3.3. Intervention Design {#sec147008}
------------------------

A randomized, placebo-controlled trial was carried out after the eligible patients were recruited between June 2013 and March 2014. We used balanced block randomization for random allocation of the patients into four groups. With a block size of four per group (A, B, C, D), there were 24 possible combinations. Each number in the random-number sequence in turn selected the next block, determining the next four participant allocations. Group SP received the supplement (one sachet daily) starting seven days before the surgery and the placebo (one sachet daily) for 30 days after the surgery. Group PS received the placebo for seven days before the surgery and the supplement for 30 days post-surgery. Group SS received the supplement for seven days before and 30 days after the surgery. Group PP received the placebo for seven days before and 30 days after the surgery.

A total of five blood samples were drawn from each patient. The first 7-mL venous sample was taken seven days before the operation, after eight hours of fasting. Then, depending on the patient's allocation, seven sachets of supplement or placebo were provided, with instructions to take one sachet daily. The supplement or placebo was taken from the day of the first blood sample until the day before the operation. On the day of the operation, the second blood sample was drawn upon arrival in the operating room. The third blood sample was drawn at the end of the operation, as the patient was leaving the operating room. The supplement or placebo was restarted after extubation on the second day postoperatively. At discharge, additional supplement/placebo sachets were given to the patients, and the fourth blood sample was drawn seven days after the operation. The fifth sample was collected at 30 days. Complications from the surgery were assessed 30 days postoperatively, including mortality rate, myocardial infarction, requirement for intra-aortic balloon pump (IABP), cerebrovascular accident, dialysis, serious or minor infections, and blood-product transfusions.

The demographic data were collected with interviews. Anthropometric assessments included measurement of weight and height. Body weight was measured to the nearest 0.1 kg using the Seca 713 scale, with the subjects minimally clothed. Height was determined using non-stretchable measuring tape, without shoes, and body mass index was then calculated by dividing weight (kg) by squared height (m^2^). All of the equipment was calibrated each morning.

Based on the Centers for Disease Control and Prevention (CDC) guidelines, a superficial wound infection was defined in this study as an infection limited to the skin and subcutaneous tissue with a clinical presentation of erythema, drainage, low-grade fever, and sternal instability, while a deep sternal wound infection (DSWI) reached the sternum but did not involve it. The diagnosis of DSWI required one of the following criteria: ([@A26207R1]) detection of an organism in a culture of mediastinal tissue or fluid; ([@A26207R2]) mediastinitis seen during the operation; or ([@A26207R3]) either chest pain, sternal instability, or fever of \> 38°C, and either purulent drainage from the mediastinum, isolation of an organism present in a blood culture, or culture of the mediastinal area ([@A26207R22], [@A26207R23]).

Based on the CDC criteria for the diagnosis of nosocomial pneumonia, clinical factors (such as fever and leukocytosis), radiological criteria (including persistent new findings on chest radiograph), and microbiologic evidence were all taken into account ([@A26207R24]).

The clinical definition of urinary tract infection (UTI) was based on the presence of a minimum of one of the following characteristics: specific and nonspecific micturition-related symptoms and signs, a positive test (nitrite test, leukocyte esterase test, dipslide, or culture), antibiotic treatment for UTI, or UTI reported in the medical record ([@A26207R25]). Specific symptoms and signs were pain before, during, or after micturition; increased frequency of micturition; abdominal pain; hematuria; foul smell; and common signs of sickness (fever \> 37.9°C or 1.5°C above baseline temperature, chills, nausea, and vomiting) ([@A26207R25]).

The diagnoses of the above-mentioned outcomes were confirmed by the surgeon. We also recorded the duration of the operation; the graft number; the cardiopulmonary bypass (CPB) time; use of exogenous insulin; administration of epinephrine, dexamethasone, and hydrocortisone during the operation and in the ICU; total blood loss; duration of intubation; and length of ICU and hospital stays.

3.4. Biochemical Assessment {#sec147009}
---------------------------

Blood was collected for measurement of glucose, insulin, and HbA1c. After transferring adequate amounts of the blood to EDTA-containing tubes for HbA1c measurement (for all samples except the third), blood samples were collected for serum separation. All blood samples were first centrifuged immediately after blood collection at 40 rpm for 10 - 30 minutes, and serum aliquots were stored at -70°C. To avoid day-to-day laboratory variables, all of the blood samples were analyzed in a single batch at the end of the clinical phase of the study. Serum glucose levels were measured spectrophotometrically on the BT 1500 autoanalyzer. Insulin was measured using ELISA (DRG kit), and HbA1c was measured by HPLC (Agilent, affinity technique). Before the start of measurement-taking, the instruments were calibrated using a reference standard with a known value to cover the range of interest. The measurement of that standard was performed with the instrument, and the result was compared with the known value.

Insulin resistance and sensitivity were calculated as follows ([@A26207R26]):
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3.5. Dietary Intake Assessment {#sec147010}
------------------------------

The patients' dietary intakes were evaluated upon enrollment and at the end of the study using 24-hour recall questionnaires. The food-processor software Nutritionist-4, modified by incorporating the Iranian food table, was used to calculate macro- and micronutrient consumptions.

3.6. Statistical Analysis {#sec147011}
-------------------------

Data processing and analysis were done using SPSS version 17 for windows (SPSS Inc., Chicago, IL, USA). Normal distribution of the data was checked using the Kolmogorov-Smirnov test. In normally distributed data, one-way ANOVA was used to compare the variables between the four groups. Chi-square and Fisher Exact tests were used for categorical variables. General linear model repeated-measures analysis with Bonferroni adjustment was used to compare changes in time within and between the four groups. Skewed data were compared using the Kruskal-Wallis test between the four groups. The significance level was set at P \< 0.05.

This trial is registered with Clinicaltrial.gov (number NCT02184507), where the trial protocol can be accessed.

4. Results {#sec147013}
==========

In this clinical trial, as shown in [Figure 1](#fig27818){ref-type="fig"}, 105 patients were randomized, and then 16 were excluded, so that a total of 89 patients remained in the trial for analysis. The reasons for the exclusions are demonstrated in the flow diagram. There were no significant differences between the four groups at baseline ([Table 1](#tbl37706){ref-type="table"}). Also, there were no significant differences between the four groups in the number of grafts, duration of surgery, administration of blood-glucose-increasing or -decreasing hormones during the operation and in the ICU, or blood loss ([Table 2](#tbl37707){ref-type="table"}).

![Flow Diagram of the Trial](ircmj-18-01-26207-i001){#fig27818}

###### Comparison of Demographic Variables and Baseline Characteristics in the Four Groups^[a](#fn40501){ref-type="table-fn"}^

  Group                               SP             PS             SS             PP              P Value
  ----------------------------------- -------------- -------------- -------------- --------------- ---------
  **Number**                          22             22             22             23              
  **Age, y**                          56.90 ± 7.5    58.72 ± 8.5    58.59 ± 6.4    55.21 ± 8.3     0.391
  **Gender**                                                                                       0.397
  Male                                12             17             16             16              
  Female                              10             5              6              6               
  **Body mass index, kg/m** ^**2**^   26.19 ± 4.56   24.37 ± 2.55   25.69 ± 3.47   25.82 ± 3.77    0.382
  **Ejection fraction, %**            51.47 ± 9.90   52.00 ± 7.40   49.95 ± 9.38   49.91 ± 10.05   0.830
  **Comorbidities**                                                                                
  Hypertension                        11 (50.0)      10 (45.4)      10 (45.4)      16 (69.5)       0.340
  Hyperlipidemia                      9 (40.9)       9 (40.9)       8 (36.3)       11 (47.8)       0.891
  **Smoking history**                                                                              
  Previous smoker                     1 (4.5)        5 (22.7)       4 (18.1)       3 (13.0)        0.305
  Current smoker                      12 (54.5)      8 (36.36)      11 (50.0)      11 (47.8)       0.744
  **Creatinine, mg/dL**               1.02 ± 0.16    1.04 ± 0.21    1.00 ± 0.26    1.04 ± 0.20     0.902

^a^Data are expressed as mean ± SD or No. (%).

###### Comparison of Surgical Parameters in the Four Groups^[a](#fn40502){ref-type="table-fn"}^

  Variables                                                     SP                 PS                 SS                 PP                 P Value
  ------------------------------------------------------------- ------------------ ------------------ ------------------ ------------------ ---------
  **Number of grafts**                                          3 (2 - 3)          3 (3 - 3)          3 (3 - 4)          3 (3 - 3)          0.209
  **Duration of surgery, min**                                  174.77 ± 39.47     180.77 ± 56.8      178.57 ± 46.5      166.08 ± 51.7      0.390
  **CPB time, min**                                             72.72 ± 19.29      76.13 ± 26.90      74.76 ± 21.13      68.34 ± 25.57      0.703
  **During operation**                                                                                                                      
  Epinephrine                                                                                                                               0.611
  Epinephrine 0.01 - 0.05, μg/kg/min                            10 (45.45)         7 (31.81)          5 (22.72)          11 (47.82)         
  Epinephrine 0.06 - 0.1, μg/kg/min                             2 (9.09)           3 (13.63)          2 (9.09)           2 (8.69)           
  Dexamethasone, 8 - 16 mg                                      4 (18.18)          6 (27.27)          4 (18.18)          6 (26.08)          0.838
  Hydrocortisone, 200 mg                                        0                  0                  0                  1 (4.34)           1.00
  **ICU**                                                                                                                                   
  Epinephrine                                                                                                                               0.505
  Epinephrine 0.01 - 0.04, μg/kg/min                            12 (54.54)         9 (40.9.)          11 (50.0)          14 (60.86)         
  Epinephrine 0.05 - 0.08, μg/kg/min                            4 (18.18)          9 (40.90)          8 (36.36)          7 (30.43)          
  Epinephrine 0.08 - 0.11, μg/kg/min                            6 (27.27)          4 (18.18)          3 (13.63)          2 (8.69)           
  Dexamethasone 2 - 8, mg                                       2 (9.09)           2 (9.09)           0                  3 (13.04)          0.504
  Hydrocortisone 10 - 200, mg                                   3 (13.63)          3 (13.63)          3 (13.63)          3 (13.04)          1.00
  Insulin 3 - 15, units                                         4 (18.18)          5 (22.72)          2 (9.09)           4 (17.39)          0.720
  **Blood loss, mL** ^**[b](#fn40503){ref-type="table-fn"}**^   815 (465 - 1185)   770 (500 - 1190)   770 (495 - 1172)   770 (540 - 1650)   0.980

Abbreviation: CPB, cardiopulmonary bypass.

^a^Data are expressed as No. (%), median (interquartile range), or mean ± SD.

^b^Total drainage during the first 48 hours postoperatively in patients with chest tubes.

The changes in the measured parameters during the trial are shown in [Table 3](#tbl37708){ref-type="table"}. The time-treatment interaction was significant for none of the parameters. Blood glucose levels increased postoperatively in the four groups, and the between-group differences were significant (0.003). In the post hoc analysis, there was a significant difference between the PP group and the SP (0.027), PS (0.026), and SS (0.004) groups.

###### Comparisons of Measured Parameters Between and Within Groups^[a](#fn40504){ref-type="table-fn"}^

  Group                 −7 Days (1)     Pre OP (2)      Post OP (3)     +7 Days (4)     +30 Days (5)    Within Groups                                                                                                    Time-Treatment Interaction   Between Groups
  --------------------- --------------- --------------- --------------- --------------- --------------- ---------------------------------------------------------------------------------------------------------------- ---------------------------- --------------------------------------------------------------------------------------------
  **Blood glucose**                                                                                     \< 0.001; 3: 1,2,4,5 (\< 0.001) ^[b](#fn40505){ref-type="table-fn"}^; 4: 1,2,3,5 (\< 0.001)                      0.236                        0.003; SP: PP (0.027) ^[b](#fn40505){ref-type="table-fn"}^; PS: PP (0.026); SS: PP (0.004)
  SP                    93.18 ± 9.9     93.95 ± 15.8    164.50 ± 44.4   106.31 ± 21.6   95.72 ± 12.8                                                                                                                                                  
  PS                    92.19 ± 11.3    92.04 ± 13.0    167.76 ± 42.0   108.47 ± 27.1   92.00 ± 11.3                                                                                                                                                  
  SS                    99.00 ± 12.6    91.66 ± 22.8    153.80 ± 37.2   99.95 ± 12.9    94.71 ± 15.6                                                                                                                                                  
  PP                    101.68 ± 13.1   110.45 ± 34.8   189.31 ± 43.3   116.50 ± 21.9   102.13 ± 16.1                                                                                                                                                 
  **Insulin (μU/mL)**                                                                                   \< 0.001; 3: 1,2,5 (\< 0.001) ^[b](#fn40505){ref-type="table-fn"}^; 3: 4 (0.001); 4: 1,3 (0.001); 4: 5 (0.018)   0.686                        0.855
  SP                    7.90 ± 3.9      11.77 ± 5.8     16.51 ± 8.4     10.84 ± 6.0     8.94 ± 4.5                                                                                                                                                    
  PS                    7.81 ± 3.9      8.49 ± 5.3      16.11 ± 11.6    12.66 ± 6.0     9.03 ± 3.6                                                                                                                                                    
  SS                    11.00 ± 11.1    9.32 ± 6.3      16.60 ± 12.6    11.50 ± 8.1     9.96 ± 5.9                                                                                                                                                    
  PP                    8.5 ± 3.4       11.05 ± 6.6     17.04 ± 11.6    12.15 ± 4.9     11.1 ± 5.0                                                                                                                                                    
  **HbA1c, %**                                                                                          0.007; 1: 2 (0.033) ^[b](#fn40505){ref-type="table-fn"}^                                                         0.375                        0.090
  SP                    6.10 ± 0.3      6.14 ± 0.4      \-              5.96 ± 0.4      5.87 ± 0.3                                                                                                                                                    
  PS                    5.93 ± 0.4      5.79 ± 0.3      \-              5.90 ± 0.4      5.67 ± 0.4                                                                                                                                                    
  SS                    6.00 ± 0.4      6.06 ± 0.5      \-              6.00 ± 0.7      5.64 ± 0.5                                                                                                                                                    
  PP                    6.12 ± 0.4      6.11 ± 0.5      \-              5.94 ± 0.7      6.05 ± 0.5                                                                                                                                                    
  **QUICKI index**                                                                                      \< 0.001; 3: 1,2,4,5 (\< 0.001) ^[b](#fn40505){ref-type="table-fn"}^; 4: 1,3 (\< 0.001)                          0.607                        0.184
  SP                    0.35 ± 0.03     0.34 ± 0.04     0.29 ± 0.02     0.33 ± 0.03     0.35 ± 0.05                                                                                                                                                   
  PS                    0.36 ± 0.04     0.36 ± 0.05     0.30 ± 0.02     0.33 ± 0.05     0.34 ± 0.02                                                                                                                                                   
  SS                    0.35 ± 0.04     0.36 ± 0.05     0.30 ± 0.03     0.34 ± 0.04     0.35 ± 0.04                                                                                                                                                   
  PP                    0.34 ± 0.02     0.33 ± 0.03     0.29 ± 0.03     0.32 ± 0.03     0.33 ± 0.03                                                                                                                                                   
  **Bennett's index**                                                                                   \< 0.001; 3: 1,2,4,5 (\< 0.001) ^[b](#fn40505){ref-type="table-fn"}^                                             0.303                        0.300
  SP                    2.04 ± 1.7      1.70 ± 1.0      0.95 ± 0.2      1.44 ± 0.5      1.60 ± 0.4                                                                                                                                                    
  PS                    2.25 ± 2.0      2.84 ± 2.9      1.04 ± 0.3      1.38 ± 0.6      1.59 ± 0.4                                                                                                                                                    
  SS                    1.83 ± 0.9      2.62 ± 3.1      1.15 ± 0.4      1.68 ± 0.8      1.78 ± 0.9                                                                                                                                                    
  PP                    1.61 ± 0.6      1.59 ± 0.7      1.18 ± 1.4      1.50 ± 1.3      1.45 ± 0.6                                                                                                                                                    
  **HOMA-IR**                                                                                           \< 0.001; 3: 1,2,4,5 (\< 0.001) ^[b](#fn40505){ref-type="table-fn"}^; 4: 1,3,5 (\< 0.001)                        0.861                        0.798
  SP                    1.80 ± 0.8      2.87 ± 1.8      6.98 ± 4.8      2.87 ± 1.7      2.13 ± 1.1                                                                                                                                                    
  PS                    1.73 ± 0.9      1.94 ± 1.4      6.42 ± 4.7      3.34 ± 1.6      2.01 ± 0.8                                                                                                                                                    
  SS                    2.29 ± 1.9      2.12 ± 1.7      6.26 ± 5.5      2.84 ± 2.3      2.29 ± 1.4                                                                                                                                                    
  PP                    2.08 ± 0.8      2.63 ± 1.7      6.62 ± 3.3      3.49 ± 1.7      2.77 ± 1.2                                                                                                                                                    
  **FIRI**                                                                                              \< 0.001; 3: 1,2,4,5 (\< 0.001) ^[b](#fn40505){ref-type="table-fn"}^; 4: 1,3,5 (\< 0.001)                        0.845                        0.601
  SP                    1.62 ± 0.8      2.59 ± 1.6      6.28 ± 4.3      2.58 ± 1.6      1.92 ± 1.0                                                                                                                                                    
  PS                    1.56 ± 0.8      1.75 ± 1.2      5.77 ± 4.2      3.00 ± 1.4      1.81 ± 0.7                                                                                                                                                    
  SS                    2.06 ± 1.7      1.91 ± 1.5      5.64 ± 5.0      2.56 ± 2.1      2.06 ± 1.3                                                                                                                                                    
  PP                    1.93 ± 0.7      2.85 ± 2.7      5.99 ± 2.9      3.18 ± 1.5      2.58 ± 1.1                                                                                                                                                    

^a^Data are expressed as mean ± SD.

^b^Pair-wise comparisons.

The surgical outcomes are demonstrated in [Table 4](#tbl37709){ref-type="table"}. Two deaths occurred: one in the SS group on the patient's first night in the ICU, and the second one in the PP group two weeks after discharge from the hospital. With regard to infectious complications, DSWI was seen in only one patient from the PP group. The superficial wound infection rate was significantly different in the four groups: 26.08% in PP, 9.09% in SP, 4.54% in PS, and 0% in SS.

###### Clinical Outcomes and Incidence of Adverse Events in the Study Patients^[a](#fn40506){ref-type="table-fn"}^

                                              SP                   PS                   SS                 PP                  P Value
  ------------------------------------------- -------------------- -------------------- ------------------ ------------------- ---------
  **Number**                                  22                   22                   22                 23                  NA
  **Death**                                   0                    0                    1 (4.54)           1 (4.3)             0.865
  **MI**                                      0                    0                    0                  1 (4.3)             1.00
  **IABP**                                    0                    0                    0                  0                   NA
  **Dialysis**                                0                    0                    0                  0                   NA
  **CVA**                                     1 (4.54)             0                    0                  1 (4.34)            1.00
  **Severe infection**                                                                                                         
  **Pneumonia (requiring ventilation)**       0                    0                    0                  0                   NA
  **DSWI**                                    0                    0                    0                  1 (4.34)            1.00
  **Minor infection**                                                                                                          
  **Pneumonia (not requiring ventilation)**   2 (9.09)             2 (9.09)             1 (4.54)           3 (13.04)           0.956
  **Superficial wound infection**             2 (9.09)             1 (4.54)             0                  6 (26.08)           0.025
  **UTI**                                     2 (9.09)             0                    0                  1 (4.34)            0.455
  **Blood transfusion**                                                                                                        
  **RBC, mL/patient**                                                                                                          
  Number (percent)                            20 (90.90)           19 (86.36)           18 (81.81)         21 (91.30)          0.886
  Unit/Patient                                3.55 ± 2.36          2.72 ± 1.79          2.74 ± 1.72        3.84 ± 2.15         0.176
  **FFP, mL/patient**                                                                                                          
  Number (percent)                            3 (13.63)            4 (18.18)            2 (9.09)           6 (26.08)           0.502
  Unit/Patient                                3.15 ± 0.78          3.85 ± 1.30          3.00 ± 1.41        4.14 ± 2.11         0.786
  **Platelets (mL/patient)**                                                                                                   
  number (percent)                            1 (4.54)             1 (4.54)             2 (9.09)           1 (4.34)            0.935
  unit/patient                                2.0                  4.0                  4.00 ± 2.8         4.0                 0.734
  **Intubation time, h**                      10 (8 - 14)          9.9 (8.2 - 12.0)     9.7 (7.1 - 11.1)   10.0 (6.5 - 13.5)   0.886
  **ICU stay, h**                             43.0 (40.5 - 48.0)   43.0 (39.7 - 51.0)   42 (41 - 43)       43 (39 - 44)        0.598
  **Hospital stay, d**                        3 (3 - 4)            4 (3 - 4)            3 (3 - 4)          4 (3 - 4)           0.311

Abbreviations:CVA, cerebrovascular accident; DSWI, deep sternal wound infection; FFP: fresh frozen plasma; IABP, intra-aortic balloon pump; MI, myocardial infarction; RBC, red blood cell; UTI, urinary tract infection.

^a^Data are expressed as No. (%), median (interquartile range), or Mean ± SD.

With regard to the participants' dietary intake, there were no significant differences in the intake of total calories, carbohydrates, protein, fat, fiber, vitamin C, vitamin E, or selenium among the four groups at the beginning and the end of the trial. In addition, there were no supplement-related complications.

5. Discussion {#sec147014}
=============

The results of the present study revealed for the first time that administration of a new metabolic conditioning supplement, whether pre- or postoperatively, led to better perioperative glycemic control and decreased post-CABG wound infection in non-diabetic patients.

Concerning glycemic control in the perioperative period, few studies have investigated the effects of metabolic conditioning using insulin-resistance-reducing agents such as arginine, glutamine, and antioxidants ([@A26207R3], [@A26207R21], [@A26207R27]). With the introduction of L-carnitine as a novel conditioning agent ([@A26207R3]), no clinical trial before now has evaluated the summative effects of glutamine, L-carnitine, and antioxidants as a metabolic conditioning supplement on surgery-induced metabolic stress. Our trial is also unique in its relatively long period of supplement administration pre- and post-surgery.

Postoperative blood glucose increased significantly in all four groups with the same pattern, but compared to the SP, PS, and SS groups, a significantly higher increase occurred in the PP group. Serum insulin levels and insulin resistance markers (HOMA-IR, FIRI) also increased significantly postoperatively, and again decreased to near the preoperative level after 30 days, but there were no significant differences between the four groups. Insulin sensitivity indices (QUICKI, Bennett's) likewise decreased immediately postoperatively, then increased by 30 days postoperatively, without any significant differences between the four groups. In addition, there were no significant differences between the four groups with regard to HbA1c levels.

As expected, our metabolic conditioning supplement led to better glycemic control in the perioperative period. In a study by Alvez et al., intravenous administration of 50 g of L-Alanyl glutamine three hours prior to surgery, in patients with critical limb ischemia undergoing operative revascularization, resulted in reduced muscle cell damage, enhanced antioxidant capacity, and improved glucose utilization by the peripheral tissues ([@A26207R28]). Glutamine supplementation has been proven to increase insulin-dependent glucose utilization in the peripheral tissues, leading to better glycemic control without changing the insulin concentration, via increasing insulin sensitivity in the periphery ([@A26207R12], [@A26207R29]).

Insulin resistance is associated with impaired mitochondrial function, which leads to decreased fatty acid oxidation. Inadequate and inefficient oxidative phosphorylation probably leads to oxidative stress and triglyceride accumulation in the skeletal muscles, which decreases insulin sensitivity ([@A26207R19], [@A26207R30]). Studies have revealed that L-carnitine concentration is reduced in diabetic patients ([@A26207R19]). Low fatty acid oxidation is secondary to reduced carnitine palmitoyltransferase (CPT) activity ([@A26207R30]), and it is proposed that exogenous carnitine supplementation may eliminate the deficit ([@A26207R19]).

We used HOMA-IR, QUICKI, Bennett's and FIRI to measure insulin resistance and sensitivity. Ljunggren et al. showed that HOMA-IR and QUICKI are unable to reflect the magnitude of surgery-induced insulin resistance. Compared to the clamp method, which is the gold standard method of assessing insulin sensitivity, HOMA-IR and QUICKI detected only 10% of postoperative insulin resistance. These static methods reflect the balance between insulin and glucose levels in the absence of any metabolic stress, while the dynamic method (the clamp technique) measures insulin resistance in hyperinsulinemic situations ([@A26207R31]). In fact, these approaches reflect different aspects of insulin resistance. The clamp method measures insulin resistance developing in peripheral tissues, such as muscle and adipose tissue, while HOMA-IR and QUICKI act as markers of hepatic insulin resistance ([@A26207R31], [@A26207R32]). Ljunggren concluded that surgery-induced insulin resistance must be attributed to metabolic alterations in the peripheral tissues rather than to hepatic metabolism ([@A26207R31]). Considering the established role of glutamine and L-carnitine in alleviating insulin resistance in the peripheral tissues, we can claim that our metabolic conditioning supplement played a role in controlling peripheral-tissue insulin resistance, and its effects were reflected in the glycemic control and infection rates. However, the static methods we used to measure insulin resistance and sensitivity (HOMA-IR, FIRI, QUICKI, and Bennett's) were unable to detect our supplement's effect on peripheral insulin resistance. We can also conclude that our metabolic conditioning agent did not have any effect on hepatic insulin resistance. Since HbA1c represents the mean glycemia level over the preceding 3-4 months ([@A26207R33]), it seems logical that changes in its value are not statistically significant.

Surgical-site infection is the third most prevalent (17%) type of all nosocomial infections in hospitalized patients, and is a major cause of morbidity and mortality in the postoperative period ([@A26207R34], [@A26207R35]). Perioperative hyperglycemia is recognized as a modifiable risk factor for surgical-site infection ([@A26207R36]). In a cohort of 149 diabetic patients undergoing colorectal resection, the mean 48-hour postoperative capillary glucose of \> 200 mg/dL was independently associated with a greater than 3-fold increase in surgical-site infections, and this relationship was independent of the dose and regimen of the postoperative insulin administration ([@A26207R37]). This means that glycemic control, rather than the dosage and regimen of the administered insulin, plays a role in infection control.

Several studies have also shown that by controlling postoperative blood glucose to levels below 11.0 mmol/L, the rate of sternal wound infections is reduced up to three times in cardiac surgery patients ([@A26207R38], [@A26207R39]). The largest randomized controlled trial (the Leuven trial), which included more than 1,500 critically ill patients, showed that with strict blood glucose control (\<110 mg/dL), compared to a level of \< 200 mg/dL, bloodstream infections were decreased and the mortality rate was reduced ([@A26207R40]). The effects of hyperglycemia on a wound take place when the wound is in the inflammatory phase of healing ([@A26207R37]). Hyperglycemia upregulates the release of pro-inflammatory mediators and suppresses the immune system ([@A26207R36]).

In our study, DSWI occurred only in one patient from the PP group, and the minor wound infection rate was significantly higher in the PP group (26.08%) compared to the SP (9.09%), PS (4.54%), and SS (0%) groups. This result is in agreement with that of blood glucose levels in our study. Since the infection rate was the lowest in the SS group, we can conclude that our novel supplement must be taken both before and after the operation to exert its best effect on postoperative infection control.

In this trial, the metabolic conditioning supplement was taken seven days prior to the operation, which is in contrast to other studies in which the conditioning agents were ingested some hours before the surgery. Therefore, the effects seen in our study are not the acute effects of the ingredients.

The strengths of our study were its new metabolic conditioning supplement and the relatively long period of its administration. A limitation of our study was the use of formulas for estimating insulin resistance and sensitivity, instead of the hyperinsulinemic normoglycemic clamp technique. It is recommended that future studies evaluate the effects of our new supplement in diabetic patients undergoing major surgery. The effect of carbohydrate-loading while taking this metabolic conditioning supplement is also worthy of further study.

Our new metabolic conditioning supplement, whether taken pre- or postoperatively, led to better perioperative glycemic control and to decreased post-CABG wound infections in non-diabetic patients. The supplement's best effect on the prevention of wound infection was seen when it was ingested both before and after the surgery.
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